PD
PROGRESSION, DISEASE, DISEASE PROGRESSION
All the patients were evaluated and administered at least two courses of treatment. In addition, the ixazomib dose was adjusted to 3 mg for 4 and 5 patients from the ICd and Id groups, respectively. Meanwhile, patients would withdraw from this trial after progression. Progression in both groups during the induction was considered to be disease progression (PD) when we analyzed the response in the induction phase. In fact, in the induction phase, two patients in the ICd group progressed after 5 and 8 cycles, respectively, and three patients in the Id group progressed after 2,3 and 7 cycles, respectively. Regardless of their disease gauge after switching to other regimens, we considered them as PD (Table Assessment of confirmed response to ICd or Id induction therapy
CR + sCR.The power of ORR (ICd vs Id) was 0.875, which was calculated by using the formulas, Overall, 75.0% of patients achieved the ORR in the entire trial, and 15 (78.9%) and 12 (70.6%) patients from the ICd and Id groups achieved a confirmed ORR (≥PR), respectively, and the value of the power between the two groups was 0.875 (Table 